Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily.
In the column, Tim discusses the results of Imagion’s latest independent review and the company’s plans moving forward while taking a deep-dive into what our team is trying to achieve – a safe, non-invasive way of looking at cancer in the body.
Imagion chief Bob Proulx reckons the oncology imaging innovator has achieved far more with its initial, early-stage breast cancer study results than investors might appreciate.
Carried out in Australia, the phase I trial showed the first signs that the company’s approach of detecting tumors with magnetic nanoparticles was safe – and it actually might work.
… continue reading the full column in the link below:
